SynthesisFrontiers in neurology2025
Intervention of Astragalus Membranaceus Extract in rats of spinal cord injury: a systematic review and meta-analysis.
Synthesis in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Spinal cord injury (SCI) causes motor, sensory and autonomic dysfunction below the level of injury and its incidence is increasing every year. Astragalus Membranaceus Extract (AME) has received attention in spinal cord injury in recent years, but its specific effects in spinal cord injury are unclear. Methods: Databases of PubMed, Embase, WOS, Cochrane Library, FMRS, Clinical trial, CNKI, VIP, and WangFang were searched from their establishment to December 1, 2024 using the following terms: "Astragalus propinquus," "Huang qi," " Results: After screening, a total of 16 studies with 996 animals were included in the review. Astragalus Membranaceus Extract (AME) administration was associated with more significant functional recovery (mean difference [MD] = 3.68, 95% CI = 2.74, 4.62). Subgroup analyses showed the best functional recovery of the spinal cord when the dose exceeded 20 units and the duration of treatment was less than 14 days. Conclusion: Our study suggests that AME has therapeutic potential for spinal cord injured rats. Further studies are needed to determine if this can be developed into a new alternative therapy through experimental and clinical studies with larger samples. Systematic review registration: Identifier: CRD42024623721, website: https://www.crd.york.ac.uk/PROSPERO/.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.